News AbbVie adds to neuroscience pipeline with $1bn Syndesi buy Four years after spinning out from Belgium's UCB, Syndesi Therapeutics and its SV2A modulator programme has been bought by AbbVie for $130 million upfront.
News UK sets 2029 timeline to end Palantir's NHS contract The UK government has said it will end the NHS's controversial contract with US tech firm Palantir, but not until 2029.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.